17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison Meeting Abstract
| Authors: | Tse, A. N.; Solit, D.; Rosen, N.; Schwartz, G. |
| Abstract Title: | 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison |
| Meeting Title: | 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 22 |
| Issue: | 14 Suppl. |
| Meeting Dates: | 2004 Jun 5-8 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2004-07-15 |
| Start Page: | 212S |
| Language: | English |
| ACCESSION: | WOS:000223512400838 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2004.22.90140.3069 |
| Notes: | Meeting Abstract: 3069 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work